NCT03498521 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT03498521
Title	A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (CUPISCO)
Acronym	CUPISCO
Recruitment	Completed
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Hoffmann-La Roche
Indications	Advanced Solid Tumor
Therapies	Atezolizumab + Paclitaxel Carboplatin Carboplatin + Paclitaxel Olaparib Vismodegib Alectinib Bevacizumab + Erlotinib Cisplatin + Gemcitabine Cobimetinib + Vemurafenib Ipatasertib + Paclitaxel Cisplatin + Paclitaxel Gemcitabine Atezolizumab Entrectinib Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Ipatasertib Carboplatin + Gemcitabine
Age Groups:	adult \| senior
Covered Countries	TUR \| ROU \| POL \| NOR \| NLD \| LVA \| ITA \| ISR \| IRL \| HUN \| HRV \| GRC \| GBR \| FRA \| FIN \| EST \| ESP \| DNK \| DEU \| CZE \| CHE \| BRA \| BGR \| AUT \| AUS

No variant requirements are available.